|
1
|
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
|
N Engl J Med
|
2004
|
8.11
|
|
2
|
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia.
|
Circulation
|
2011
|
3.33
|
|
3
|
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
|
Lancet
|
2007
|
3.11
|
|
4
|
Improved outcome in central nervous system aspergillosis, using voriconazole treatment.
|
Blood
|
2005
|
2.97
|
|
5
|
Combination antifungal therapy for invasive aspergillosis: a randomized trial.
|
Ann Intern Med
|
2015
|
2.18
|
|
6
|
Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients.
|
Drugs
|
2007
|
2.09
|
|
7
|
Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.
|
Haematologica
|
2010
|
1.91
|
|
8
|
Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
|
Pharmacotherapy
|
2008
|
1.79
|
|
9
|
Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients.
|
Br J Haematol
|
2004
|
1.73
|
|
10
|
Patients at high risk of invasive fungal infections: when and how to treat.
|
Drugs
|
2008
|
1.62
|
|
11
|
Central venous catheter (CVC)-related infections in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
|
Ann Hematol
|
2003
|
1.62
|
|
12
|
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
|
Clin Infect Dis
|
2006
|
1.54
|
|
13
|
Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?
|
Leuk Lymphoma
|
2010
|
1.40
|
|
14
|
Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
|
Clin Infect Dis
|
2012
|
1.39
|
|
15
|
Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
|
Ann Hematol
|
2008
|
1.17
|
|
16
|
Mucormycosis treated with posaconazole: review of 96 case reports.
|
Crit Rev Microbiol
|
2012
|
1.15
|
|
17
|
Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study.
|
Infect Control Hosp Epidemiol
|
2003
|
1.15
|
|
18
|
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology.
|
Eur J Cancer
|
2009
|
1.13
|
|
19
|
Recent developments in the management of invasive fungal infections in patients with hematological malignancies.
|
Ann Hematol
|
2004
|
1.08
|
|
20
|
Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry.
|
Antimicrob Agents Chemother
|
2010
|
1.07
|
|
21
|
Therapeutic drug monitoring of voriconazole and posaconazole.
|
Pharmacotherapy
|
2011
|
1.07
|
|
22
|
Posaconazole concentrations in the central nervous system.
|
J Antimicrob Chemother
|
2008
|
1.06
|
|
23
|
HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases.
|
Mycoses
|
2006
|
1.06
|
|
24
|
Invasive candidiasis and candidemia: from current opinions to future perspectives.
|
Expert Opin Investig Drugs
|
2009
|
1.03
|
|
25
|
Fungal endocarditis.
|
Curr Opin Infect Dis
|
2013
|
1.00
|
|
26
|
Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry.
|
Int J Antimicrob Agents
|
2009
|
0.98
|
|
27
|
Intracellular concentrations of posaconazole in different compartments of peripheral blood.
|
Antimicrob Agents Chemother
|
2010
|
0.97
|
|
28
|
A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
|
J Infect
|
2007
|
0.97
|
|
29
|
Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
|
Ann Hematol
|
2013
|
0.96
|
|
30
|
Our 2014 approach to mucormycosis.
|
Mycoses
|
2014
|
0.96
|
|
31
|
PTX3 deficiency and aspergillosis.
|
N Engl J Med
|
2014
|
0.96
|
|
32
|
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.
|
Haematologica
|
2013
|
0.93
|
|
33
|
Posaconazole: a next-generation triazole antifungal.
|
Future Microbiol
|
2007
|
0.93
|
|
34
|
Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death.
|
Clin Infect Dis
|
2008
|
0.92
|
|
35
|
Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.
|
Antimicrob Agents Chemother
|
2011
|
0.91
|
|
36
|
Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials.
|
Am J Nephrol
|
2013
|
0.90
|
|
37
|
Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).
|
Ann Hematol
|
2015
|
0.89
|
|
38
|
Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.
|
Antimicrob Agents Chemother
|
2010
|
0.89
|
|
39
|
Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman.
|
Int J Antimicrob Agents
|
2006
|
0.89
|
|
40
|
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
|
Antimicrob Agents Chemother
|
2009
|
0.88
|
|
41
|
Aspergillus PCR testing: results from a prospective PCR study within the AmBiLoad trial.
|
Eur J Haematol
|
2010
|
0.87
|
|
42
|
Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab.
|
Ann Hematol
|
2008
|
0.87
|
|
43
|
Diagnosis and treatment of documented infections in neutropenic patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
|
Ann Hematol
|
2003
|
0.86
|
|
44
|
Antifungal treatment strategies in high risk patients.
|
Mycoses
|
2008
|
0.85
|
|
45
|
Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.
|
Future Microbiol
|
2006
|
0.85
|
|
46
|
Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.
|
Antimicrob Agents Chemother
|
2013
|
0.85
|
|
47
|
Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
|
Value Health
|
2006
|
0.84
|
|
48
|
Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting.
|
Ann Hematol
|
2007
|
0.84
|
|
49
|
Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy.
|
Mycoses
|
2011
|
0.83
|
|
50
|
Anidulafungin--state of affairs from a clinical perspective.
|
Mycoses
|
2007
|
0.82
|
|
51
|
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.
|
Br J Haematol
|
2005
|
0.82
|
|
52
|
Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial.
|
Int J Antimicrob Agents
|
2011
|
0.81
|
|
53
|
Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
|
Ann Hematol
|
2012
|
0.81
|
|
54
|
Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
|
N Engl J Med
|
2002
|
0.81
|
|
55
|
Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.
|
Ann Hematol
|
2014
|
0.81
|
|
56
|
Our 2014 approach to candidaemia.
|
Mycoses
|
2014
|
0.80
|
|
57
|
Aspergillosis of bones and joints - a review from 2002 until today.
|
Mycoses
|
2014
|
0.80
|
|
58
|
Antifungal prophylaxis for invasive mycoses in high risk patients.
|
Curr Opin Infect Dis
|
2006
|
0.80
|
|
59
|
Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.
|
Mycoses
|
2011
|
0.80
|
|
60
|
Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression.
|
Curr HIV Res
|
2008
|
0.80
|
|
61
|
Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients.
|
Haematologica
|
2011
|
0.80
|
|
62
|
Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood.
|
Int J Antimicrob Agents
|
2012
|
0.79
|
|
63
|
Zygomycosis--current epidemiological aspects.
|
Mycoses
|
2007
|
0.79
|
|
64
|
Development of new strategies for early diagnosis of mucormycosis from bench to bedside.
|
Mycoses
|
2014
|
0.78
|
|
65
|
Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation.
|
Mycoses
|
2006
|
0.78
|
|
66
|
Treatment options in candidaemia.
|
Mycoses
|
2007
|
0.78
|
|
67
|
Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
|
Mycoses
|
2013
|
0.78
|
|
68
|
Intracellular concentrations of anidulafungin in different compartments of the peripheral blood.
|
Int J Antimicrob Agents
|
2013
|
0.78
|
|
69
|
Treatment of invasive candidiasis with echinocandins.
|
Mycoses
|
2009
|
0.78
|
|
70
|
Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection.
|
Am J Respir Crit Care Med
|
2015
|
0.78
|
|
71
|
Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT.
|
Support Care Cancer
|
2010
|
0.78
|
|
72
|
Disseminated Fusariosis in Immunocompromised Children - Analysis of Recent Cases Identified in the Global FungiScope Registry.
|
Pediatr Infect Dis J
|
2016
|
0.77
|
|
73
|
Combined intra- and extracranial cryptococcal infection of a 20-year-old patient in right temporal area.
|
J Oral Maxillofac Surg
|
2010
|
0.76
|
|
74
|
Choosing a study population for the evaluation of antifungal prophylaxis.
|
Clin Infect Dis
|
2005
|
0.76
|
|
75
|
Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole.
|
Int J Hematol
|
2008
|
0.76
|
|
76
|
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
|
J Antimicrob Chemother
|
2016
|
0.75
|
|
77
|
Current controversies in treating invasive zygomycosis.
|
J Pediatr Hematol Oncol
|
2010
|
0.75
|
|
78
|
Itraconazole versus fluconazole for antifungal prophylaxis.
|
Ann Intern Med
|
2004
|
0.75
|
|
79
|
Comment on: Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
|
J Antimicrob Chemother
|
2005
|
0.75
|
|
80
|
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.
|
Clin Infect Dis
|
2006
|
0.75
|
|
81
|
[Current development in the diagnostics and therapy of systemic fungal infections in cancer patients].
|
Wien Med Wochenschr
|
2004
|
0.75
|
|
82
|
Second-line treatment in invasive mould infections.
|
Mycoses
|
2006
|
0.75
|
|
83
|
Surgical site infections: current management and role of new antibiotics.
|
Curr Opin Infect Dis
|
2019
|
0.75
|
|
84
|
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
|
J Antimicrob Chemother
|
2017
|
0.75
|
|
85
|
[Echinocandins in invasive candidiasis].
|
Med Klin (Munich)
|
2008
|
0.75
|
|
86
|
Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.
|
Pharm Res
|
2014
|
0.75
|
|
87
|
Anidulafungin: advantage for the newcomer?
|
Expert Rev Clin Pharmacol
|
2008
|
0.75
|
|
88
|
Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients.
|
Expert Opin Pharmacother
|
2010
|
0.75
|
|
89
|
[Zygomycosis after hematogeneic stem cell transplantation--a current problem?].
|
Med Klin (Munich)
|
2006
|
0.75
|
|
90
|
[Vaccination of the immunocompromised host].
|
Wien Med Wochenschr
|
2004
|
0.75
|